Sectors
GYRE
Gyre Therapeutics, Inc.
6.57
2 x 6.56
1 x 6.59
bid
ask
-
0.02
0.30%
2 @ 07:30 PM
6.57 +0.00 (0.00%)
| Ytd | -6.94% | |
| 1y | -15.12% |
6.47
day range
6.64
5.44
52 week range
9.42
| Open | 6.60 | Prev Close | 6.59 | Low | 6.47 | High | 6.64 | Mkt Cap | 696.64M |
| Vol | 41.71K | Avg Vol | 81.35K | EPS | -0.21 | P/E | N/A | Forward P/E | 25.22 |
| Beta | 1.92 | Short Ratio | 21.22 | Inst. Own | 1.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 6.45 | 200-d Avg | 7.18 | 1yr Est | 0.00 |
| Income Statement | |||
| Total Revenue | 29.11M | ||
| Revenues (USD) | 29.11M | ||
| Cost of Revenue | 2.21M | ||
| Gross Profit | 26.90M | ||
| Operating Expenses | 41.26M | ||
| Research and Development Expense | 19.14M | ||
| Selling, General and Administrative Expense | 21.62M | ||
| Operating Income | -14.36M | ||
| Income Tax Expense | -164.00K | ||
| Net Income | -10.60M | ||
| Net Income Common Stock | -11.66M | ||
| Net Income Common Stock (USD) | -11.66M | ||
| Consolidated Income | -14.27M | ||
| Net Income to Non-Controlling Interests | -3.66M | ||
| Earnings per Basic Share | -0.12 | ||
| Earnings per Basic Share (USD) | -0.12 | ||
| Earnings per Diluted Share | -0.12 | ||
| Earning Before Interest & Taxes (EBIT) | -10.77M | ||
| Earning Before Interest & Taxes (USD) | -10.77M | ||
| Preferred Dividends Income Statement Impact | 1.06M | ||
| Weighted Average Shares | 100.64M | ||
| Weighted Average Shares Diluted | 100.64M | ||
| Balance Sheet | |||
| Cash and Equivalents | 43.29M | ||
| Cash and Equivalents (USD) | 43.29M | ||
| Investments | 60.19M | ||
| Investments Current | 31.74M | ||
| Investments Non-Current | 28.44M | ||
| Trade and Non-Trade Receivables | 28.02M | ||
| Current Assets | 122.07M | ||
| Property, Plant & Equipment Net | 27.28M | ||
| Total Assets | 199.26M | ||
| Debt Current | 1.39M | ||
| Total Debt | 3.42M | ||
| Current Liabilities | 28.66M | ||
| Debt Non-Current | 2.03M | ||
| Total Liabilities | 34.34M | ||
| Accumulated Retained Earnings (Deficit) | -137.96M | ||
| Accumulated Other Comprehensive Income | 1.49M | ||
| Shareholders Equity | 107.93M | ||
| Shareholders Equity (USD) | 107.93M | ||
| Assets Non-Current | 77.18M | ||
| Total Debt (USD) | 3.42M | ||
| Deferred Revenue | 829.00K | ||
| Goodwill and Intangible Assets | 4.53M | ||
| Inventory | 11.43M | ||
| Liabilities Non-Current | 5.67M | ||
| Trade and Non-Trade Payables | 6.32M | ||
| Tax Assets | 9.28M | ||
| Tax Liabilities | 2.15M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.71M | ||
| Net Cash Flow from Financing | -8.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -6.34M | ||
| Capital Expenditure | -255.00K | ||
| Issuance (Purchase) of Equity Shares | 200.00K | ||
| Net Cash Flow from Investing | 9.76M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 11.04M | ||
| Net Cash Flow from Operations | -16.73M | ||
| Effect of Exchange Rate Changes on Cash | 643.00K | ||
| Share Based Compensation | 2.08M | ||